- Home
- CCD vs TERN Comparison
CCD vs TERN Comparison
Compare CCD & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCD
- TERN
- Stock Information
- Founded
- CCD 2014
- TERN 2017
- Country
- CCD United States
- TERN United States
- Employees
- CCD N/A
- TERN N/A
- Industry
- CCD Trusts Except Educational Religious and Charitable
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- CCD Finance
- TERN Health Care
- Exchange
- CCD Nasdaq
- TERN Nasdaq
- Market Cap
- CCD 555.7M
- TERN 634.5M
- IPO Year
- CCD N/A
- TERN 2021
- Fundamental
- Price
- CCD $20.81
- TERN $7.22
- Analyst Decision
- CCD
- TERN Buy
- Analyst Count
- CCD 0
- TERN 6
- Target Price
- CCD N/A
- TERN $13.99
- AVG Volume (30 Days)
- CCD 96.1K
- TERN 1.2M
- Earning Date
- CCD 01-01-0001
- TERN 08-05-2025
- Dividend Yield
- CCD 10.61%
- TERN N/A
- EPS Growth
- CCD N/A
- TERN N/A
- EPS
- CCD N/A
- TERN N/A
- Revenue
- CCD N/A
- TERN N/A
- Revenue This Year
- CCD N/A
- TERN N/A
- Revenue Next Year
- CCD N/A
- TERN N/A
- P/E Ratio
- CCD N/A
- TERN N/A
- Revenue Growth
- CCD N/A
- TERN N/A
- 52 Week Low
- CCD $16.93
- TERN $1.87
- 52 Week High
- CCD $24.68
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- CCD 63.79
- TERN 59.36
- Support Level
- CCD $20.37
- TERN $6.78
- Resistance Level
- CCD $20.59
- TERN $7.78
- Average True Range (ATR)
- CCD 0.20
- TERN 0.49
- MACD
- CCD 0.05
- TERN -0.02
- Stochastic Oscillator
- CCD 88.88
- TERN 63.82
About CCD Calamos Dynamic Convertible & Income Fund
Calamos Dynamic Convertible and Income Fund operates as a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It predominantly invests in a portfolio of convertible securities, investment grade and below investment grade bonds, loans, equity-linked notes, and floating rate securities.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.